Aarti Drugs Limited has announced a significant investment decision to strengthen its pharmaceutical operations through its subsidiary company. The Finance & Investment Committee approved the investment during its meeting held on March 7, 2026, demonstrating the company's commitment to expanding its pharmaceutical manufacturing capabilities.

Investment Details and Structure

The committee has approved an investment of up to ₹10,00,00,000 in equity shares of Pinnacle Life Science Private Limited, a wholly owned subsidiary of Aarti Drugs Limited. The investment will be executed through subscription to a rights issue, with share allotment scheduled to be completed on or before March 20, 2026.

About Pinnacle Life Science

Pinnacle Life Science Private Limited, incorporated on January 15, 2003, operates as a pharmaceutical formulations manufacturer with a diverse product portfolio. The company specializes in oncology, cardiovascular, anti-infectives, and diabetics segments, maintaining a strong international presence by exporting products to over 30 countries while also serving the domestic Indian market.

Financial Performance Overview

Pinnacle's financial performance over the last three years shows varying turnover levels:

Strategic Rationale and Impact

The investment proceeds will be utilized by Pinnacle for financing expansion and capex plans, along with other general corporate purposes. This investment aligns with Aarti Drugs Limited's core pharmaceutical business, as both companies operate in the same industry segment. The transaction is being conducted on an arm's length basis, maintaining transparency in the related party transaction.

Regulatory Compliance

The investment has been approved under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As this constitutes a related party transaction with a wholly owned subsidiary, no additional governmental or regulatory approvals are required. Post-allotment, Pinnacle Life Science will continue to remain a wholly owned subsidiary of Aarti Drugs Limited, maintaining the existing ownership structure.

Aarti Drugs Limited has announced the incorporation of a new step-down subsidiary in Chile, expanding its international pharmaceutical operations through its existing subsidiary structure. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations on March 2, 2026.

New Subsidiary Formation

The newly incorporated entity, Tripharma Chile SpA, was established on February 27, 2026, through Pinnacle Chile SpA, which is already a subsidiary of Aarti Drugs Limited. The certificate of registration was processed by the Registry of Companies and Societies, Government of Chile, on February 27, 2026, with company officials being notified on March 2, 2026.

Business Operations and Objectives

Tripharma Chile SpA will operate in the pharmaceutical industry, focusing on marketing formulation drugs and participating in both tender and private markets in Chile. The company's business model aligns with the operations of its holding companies, maintaining consistency within the Aarti Drugs group's pharmaceutical focus.

Corporate Structure

The incorporation creates a multi-tiered subsidiary structure where Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs Limited. Pinnacle Chile SpA, which is a direct subsidiary of Aarti Drugs Limited, holds 100% shareholding in the newly formed Tripharma Chile SpA. This structure allows Aarti Drugs to maintain operational control while establishing a local presence in the Chilean pharmaceutical market.

Financial and Regulatory Details

The incorporation involved a cash consideration of Chilean Peso 10,00,000 as share capital contribution, distributed across 10,00,000 shares. The company confirmed that no specific governmental or regulatory approvals were required for this incorporation, streamlining the establishment process in Chile.

This strategic move represents Aarti Drugs Limited's continued expansion in international markets, particularly in South America, through its pharmaceutical operations and subsidiary network.